Loading
CASP8 (Caspase-8) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Cervical cancer and 5 more.
Thiol protease that plays a key role in programmed cell death by acting as a molecular switch for apoptosis, necroptosis and pyroptosis, and is required to prevent tissue damage during embryonic development and adulthood. Initiator protease that induces extrinsic apoptosis by mediating cleavage and activation of effector caspases responsible for FAS/CD95-mediated and TNFRSF1A-induced cell death. Cleaves and activates effector caspases CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Conatumumab. Open Targets scores its association with cancer at 0.82 (direct and indirect evidence; datatypes literature 0.99, animal model 0.49, genetic association 0.70, somatic mutation 0.93). IntOGen calls it a driver in 17 cohorts (2 activating, 15 loss-of-function), covering Basal Cell Carcinoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma and others.
In plain words · CASP8 (Caspase-8) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Cervical cancer and 5 more.
CASP8 (Caspase-8) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Cervical cancer and 5 more.
Thiol protease that plays a key role in programmed cell death by acting as a molecular switch for apoptosis, necroptosis and pyroptosis, and is required to prevent tissue damage during embryonic development and adulthood.
No product in this corpus aims at CASP8 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CASP8: RNA tissue enhanced (bone marrow 44 nTPM); high antibody staining in 17 normal tissues; highest cancer staining pancreatic cancer (10 of 11 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Head and neck squamous cell carcinoma, Skin cancer (all types), Cervical cancer, Breast cancer (all types), Nasopharyngeal carcinoma, Bladder & urothelial cancer, Lymphoma and more); Open Targets associates it with 2 specific cancer types at or above 0.5 (autoimmune lymphoproliferative syndrome type 2B, head and neck squamous cell carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q14790; CIViC gene CASP8; IntOGen CASP8; Human Protein Atlas CASP8 tissue; Open Targets ENSG00000064012 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Boldin M.P. et al, Cell, 1996, "Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death". Source.
Sources: HGNC HGNC:1509 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14790 (protein name, function text, keywords and locations (REST API)); CIViC gene CASP8 (2 evidence items, 0 assertions, 2 variants; diseases: Neuroblastoma, Ewing Sarcoma Of Bone (GraphQL API, CC0)); Open Targets ENSG00000064012 (association with cancer (MONDO_0004992) 0.82; per-cancer scores at or above 0.5: colorectal cancer 0.55, ovarian cancer 0.56, melanoma 0.57, head and neck squamous cell carcinoma 0.66, skin cancer 0.63, basal cell carcinoma 0.52 (GraphQL API, CC0)); IntOGen CASP8 (driver in 17 cohorts (Act 2, LoF 15); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Thiol protease that plays a key role in programmed cell death by acting as a molecular switch for apoptosis, necroptosis and pyroptosis, and is required to prevent tissue damage during embryonic development and adulthood. Initiator protease that induces extrinsic apoptosis by mediating cleavage and activation of effector caspases responsible for FAS/CD95-mediated and TNFRSF1A-induced cell death. Cleaves and activates effector caspases CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. Binding to the adapter molecule FADD recruits it to either receptor FAS/TNFRSF6 or TNFRSF1A. The resulting aggregate called the death-inducing signalling complex (DISC) performs CASP8 proteolytic activation. The active dimeric enzyme is then liberated from the DISC and free to activate downstream apoptotic proteases. Location: Cytoplasm; Nucleus; Cell projection, lamellipodium (UniProt). Locus 2q33.1 (HGNC).
RNA: tissue enhanced (bone marrow 44 nTPM), detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Breast, Bronchus, Cerebellum, Cervix, Endometrium, Nasopharynx.
Medium only: melanoma, skin cancer, thyroid cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CASP8" OR ABSTRACT:"CASP8" OR TITLE:"caspase 8" OR ABSTRACT:"caspase 8" OR TITLE:"Caspase-8" OR ABSTRACT:"Caspase-8" OR TITLE:"MCH5" OR ABSTRACT:"MCH5" OR TITLE:"FLICE" OR ABSTRACT:"FLICE" OR TITLE:"Casp-8" OR ABSTRACT:"Casp-8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CASP8, not a curated reading list.
Shares Nasopharyngeal carcinoma, Cervical cancer, Bladder & urothelial cancer, CIViC.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Cervical cancer, CIViC.
Shares Nasopharyngeal carcinoma, Bladder & urothelial cancer, IntOGen, Head and neck squamous cell carcinoma.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), CIViC, IntOGen.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), CIViC, IntOGen.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), IntOGen, Breast cancer (all types).
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Cervical cancer, IntOGen.